Literature DB >> 31892548

Current Treatment of Colorectal Liver Metastasis as a Chronic Disease.

Niels Michael Dörr1, Michael Bartels2, Mehmet Haluk Morgul3.   

Abstract

BACKGROUND/AIM: The treatment of colorectal liver metastases is challenging and requires multidisciplinary strategies. Unfortunately, only 25% of patients with colorectal liver metastases are eligible for liver resection. Due to the variety of therapeutic approaches, this percentage has increased; however, at the same time, the definition of resectability has become complex. The aim of this review was to provide an overview of current surgical therapies for colorectal liver metastases.
MATERIALS AND METHODS: Relevant studies published before June 2019 were identified using PubMed. A comprehensive review of the current literature regarding the impact of and innovations in the therapy of colorectal liver metastases was carried out.
RESULTS: The major advances in the resectability of colorectal liver metastases were effective chemotherapy regimens and preoperative liver volume modulation techniques. In addition, health professionals face rapid technical developments in interventional local therapies, minimally invasive surgery, robot-assisted surgery and even liver transplantation.
CONCLUSION: Currently, liver metastases from colorectal cancer are considered a chronic disease. In cases of advanced colorectal liver metastases, the definition of resectability and the indications for surgical treatment should be exclusively determined by experienced hepatobiliary surgeons. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Colorectal liver metastases; chronic disease; resectability; surgery

Mesh:

Year:  2020        PMID: 31892548     DOI: 10.21873/anticanres.13921

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series.

Authors:  David Schöler; Mirco Castoldi; Markus S Jördens; Max Schulze-Hagen; Christiane Kuhl; Verena Keitel; Tom Luedde; Christoph Roderburg; Sven H Loosen
Journal:  PLoS One       Date:  2021-08-18       Impact factor: 3.240

2.  Pros and Cons of Portal Vein Embolization With Hematopoietic Stem Cells Application in Colorectal Liver Metastases Surgery.

Authors:  Vladislav Treska; Jan Bruha; Vaclav Liska; Jakub Fichtl; Kristyna Prochazkova; Tereza Petrakova; Petr Hosek
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 3.  The art of robotic colonic resection: a review of progress in the past 5 years.

Authors:  Hongyi Liu; Maolin Xu; Rong Liu; Baoqing Jia; Zhiming Zhao
Journal:  Updates Surg       Date:  2021-01-22

4.  Inhibition of ERKs/Akt-Mediated c-Fos Expression Is Required for Piperlongumine-Induced Cyclin D1 Downregulation and Tumor Suppression in Colorectal Cancer Cells.

Authors:  Feng Gao; Li Zhou; Ming Li; Wenbin Liu; Shuting Yang; Wei Li
Journal:  Onco Targets Ther       Date:  2020-06-15       Impact factor: 4.147

Review 5.  The Neuropeptide System and Colorectal Cancer Liver Metastases: Mechanisms and Management.

Authors:  Aldona Kasprzak; Agnieszka Adamek
Journal:  Int J Mol Sci       Date:  2020-05-15       Impact factor: 5.923

6.  Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.

Authors:  Sven H Loosen; Max Schulze-Hagen; Mihael Vucur; Joao Gorgulho; Pia Paffenholz; Fabian Benz; Raphael Mohr; Münevver Demir; Alexander Wree; Christiane Kuhl; Christian Trautwein; Frank Tacke; Philipp Bruners; Tom Luedde; Christoph Roderburg
Journal:  JGH Open       Date:  2021-02-01

7.  Surgery for Liver Metastasis of Non-Colorectal and Non-Neuroendocrine Tumors.

Authors:  Shadi Katou; Franziska Schmid; Carolina Silveira; Lina Schäfer; Tizian Naim; Felix Becker; Sonia Radunz; Mazen A Juratli; Leon Louis Seifert; Hauke Heinzow; Benjamin Struecker; Andreas Pascher; M Haluk Morgul
Journal:  J Clin Med       Date:  2022-03-29       Impact factor: 4.241

8.  MRI-guided percutaneous thermoablation in combination with hepatic resection as parenchyma-sparing approach in patients with primary and secondary hepatic malignancies: single center long-term experience.

Authors:  Moritz T Winkelmann; Rami Archid; Georg Gohla; Gerald Hefferman; Jens Kübler; Jakob Weiss; Stephan Clasen; Konstantin Nikolaou; Silvio Nadalin; Rüdiger Hoffmann
Journal:  Cancer Imaging       Date:  2020-05-27       Impact factor: 3.909

9.  Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies.

Authors:  Theresa H Wirtz; Sven H Loosen; Max Schulze-Hagen; Joao Gorgulho; Jennis Kandler; Markus Joerdens; Münevver Demir; Raphael Mohr; Philipp Bruners; Christiane Kuhl; Christian Trautwein; Marie-Luise Berres; Frank Tacke; Tom Luedde; Christoph Roderburg
Journal:  Clin Transl Sci       Date:  2021-07-19       Impact factor: 4.689

10.  Laparoscopic Resection of Synchronous Liver Metastasis Involving the Left Hepatic Vein and the Common Trunk Bifurcation: A Strategy of Parenchyma-Sparing Resection with Left Sectionectomy and 4a Subsegmentectomy by Arantius Approach.

Authors:  Filippo Banchini; Enrico Luzietti; Gerardo Palmieri; Deborah Bonfili; Andrea Romboli; Luigi Conti; Patrizio Capelli
Journal:  Healthcare (Basel)       Date:  2022-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.